Uncategorized Archives - Page 31 of 87 - PsychedelicNewsWire (PNW)

ThursdayJul 08, 2021 1:00 pm

Four Clinical Trials That Could Change Treatment for Mental Health Conditions

In the last decade, a lot of clinical research on psychedelic substances has been conducted, with many scientists focusing on their use in treating psychological and mental ailments. This has also led to a surge in investments into psychedelic research, with many results heralding psychedelics as effective alternative medications for various ailments. Before being classified under Schedule I of the Controlled Substances Act in the United States, psychedelics had been used for both medicinal and recreational purposes by different indigenous tribes and cultures for centuries, only becoming popular in Western medicine in the late 1950s and 1960s. Recent studies on…

WednesdayJul 07, 2021 2:15 pm

UNC Prof Determined to Get the High Out of Psychedelics

The ongoing psychedelic renaissance has brought on a new wave of research on psychedelics, with many studies discovering the various therapeutic benefits that the substances possess. In the last 10 years, privately financed clinical studies have demonstrated the value of psychedelics in treating substance use disorders, anxiety and depression, with MDMA being found to be efficacious in the treatment of PTSD. Earlier in 2019, the Food and Drug Administration gave its approval to the first-ever ketamine-based antidepressant. Studies on psilocybin have also found that the compound is very effective in treating depression. However, Dr. Bryan Roth from the UNC School…

TuesdayJul 06, 2021 2:00 pm

New Study to Look into the Use of Psychedelics for Burnout Among Clinicians

The coronavirus pandemic has affected economies and industries around the world, and while things seem to be getting back on track in some sectors, frontline workers still remain the most affected by COVID-19, which has caused millions to die. Data from a poll conducted by EClinicalMedicine, the Lancet, shows that almost 50% of healthcare workers suffered burnouts, nearly 45% suffered work overload, more than 35% admitted to being depressed or feeling anxiety, and more than 60% feared that they had been exposed to the disease and/or could be transmitting it. The survey, which had more than 20,000 healthcare workers from…

TuesdayJul 06, 2021 9:15 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Featured in Stifel Report; Price Target Raised by C$12, Rated as Spec Buy

CYBN continues to demonstrate good progress with its preclinical activities on its novel drug programs, report observed Stifel also notes selecting indications with large patient pools, an understated market size, and potential for multiple synergies across development and distribution Report incorporates both CYB001 and CYB004 into valuation As Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, continues to develop its multimolecule strategy, people are paying attention. A recent Stifel report raised Cybin’s price target by C$12, up from C$4 to C$15, and maintained the company’s speculative buy rating (https://ibn.fm/HLcxX). “CYBN continues to demonstrate good progress…

FridayJul 02, 2021 12:00 pm

Study Finds Men Who Use Psychedelics Less Likely to Be Violent to Their Partners

Research conducted by scientists from the University of British Columbia has discovered evidence that men who have used psychedelic substances in the past have decreased chances of being involved with violence against their partners. In the study, which was reported in the “Journal of Psychopharmacology,” the scientists note that their findings do not apply to women. The study’s lead author, Michelle Thiessen, who also happens to be a clinical psychology graduate student from the institution’s Okanagan campus, stated that the researchers’ focus was on the link between violence and psychedelic substances. She explained that while the link between violence and…

FridayJul 02, 2021 10:23 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share its Drug Development Pipeline and the Company’s Progress in the Psych Investor Summit

Tryp Therapeutics will be participating in the second global Psych Investor Summit: Research and Development The virtual presentation is scheduled for July 7 from 11:50 a.m. to 12:50 p.m. EDT It will focus on the psychedelics industry, showcasing the latest research and development within the sector Mr. Greg McKee, Chairman and CEO of Tryp Therapeutics, will share information on the company, along with its drug development pipeline In an official statement dated June 24, 2021, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) confirmed that it would participate in the Psych Investor Summit: Research and Development. The virtual event, scheduled on Wednesday,…

ThursdayJul 01, 2021 3:15 pm

Scientists Develop Synthetic Ibogaine Compound That Can Treat Addiction, Depression

Researchers from the University of California-Davis have developed a synthetic version of ibogaine, a psychedelic drug that is nonhallucinogenic. The synthetic compound has the potential to treat various psychiatric disorders, including depression and addiction. The researchers’ findings were reported in the “Nature” journal. David Olson, an assistant professor of chemistry at the institution who was also the senior author of the paper, stated that while psychedelic drugs were powerful substances that affected the brain, it was a shame that very little was known about them. What is known is that ibogaine is extracted from the Tabernanthe iboga plant. Various anecdotal…

WednesdayJun 30, 2021 2:07 pm

XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Mescaline Program for Psychedelic Therapies is on Track

XPhyto Therapeutics Corp (OTCQB: XPHYF) announced its GMP mescaline synthesis program is “on schedule” The program, which started in early 2021, is slated for completion in late Q3 2021 The first initial production batches were completed successfully, marking a significant milestone for the program Mescaline will form a critical component in XPhyto’s psychedelic medicine program and work towards providing a foundation for its drug formulation and clinical validation work XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) recently announced that its Good Manufacturing Practices (“GMP”) mescaline synthesis program in North America is “on schedule” for completion in late Q3 2021…

WednesdayJun 30, 2021 2:00 pm

New Texas Law Mandates Study of Psychedelics’ Effects on Military Vets

Gov. Greg Abbott of Texas recently approved a legislation that makes it compulsory for the state to look into the therapeutic potential of psychedelics. This approval was made only a few days after the governor signed a separate bill to expand the state’s medical cannabis program. Under the psychedelics bill, the state of Texas will be required to conduct research on the medical benefits and risks of ketamine, MDMA and psilocybin for military veterans, in collaboration with a military-focused medical center and the Baylor College of Medicine. The bill also makes it mandatory for a clinical trial on psilocybin for…

WednesdayJun 30, 2021 1:27 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Ships Initial Order of 0.5 Gram Vape Cartridges

Pure Extracts announced initial shipment of 0.5 gram vape cartridges to Alberta Gaming, Liquor & Cannabis CBD vape market has experienced strong growth in recent times, with one market research firm forecasting sector to be worth over $28bn by 2027 Pure Extracts has simultaneously sought to broaden its SKU’s within vape sector, commencing manufacture of larger, 1 gram FSO vape cartridge to better cater to changing customer demand patterns Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on the cannabis, hemp, functional mushrooms, and rapidly emerging psychedelic sector, announced that its whole owned subsidiary,…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized